Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AKCA

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

Akcea Therapeutics logo

About Akcea Therapeutics Stock (NASDAQ:AKCA)

Key Stats

Today's Range
$18.17
$18.17
50-Day Range
$18.13
$18.17
52-Week Range
$8.00
$21.70
Volume
N/A
Average Volume
361,806 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Receive AKCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKCA Stock News Headlines

Arcturus Therapeutics Holdings Inc ARCT
AKCA Historical Data
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
Akcea Therapeutics Inc (AKCA)
See More Headlines

AKCA Stock Analysis - Frequently Asked Questions

Akcea Therapeutics, Inc. (NASDAQ:AKCA) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.14. The company's revenue was down 15.9% compared to the same quarter last year.

Akcea Therapeutics (AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC).

Company Calendar

Last Earnings
8/04/2020
Today
11/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKCA
Fax
N/A
Employees
248
Year Founded
N/A

Profitability

Net Income
$40.77 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$488.54 million
Cash Flow
$0.51 per share
Book Value
$5.78 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.45
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:AKCA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners